Universe Pharmaceuticals Inc

Universe Pharmaceuticals Inc(UPC)股票分析

$4.900

-0.136 (-2.78%)收盤時

Loading chart…
High
5.550
Open
4.950
VWAP
5.01
Vol
18.26K
Mkt Cap
9.26M
Low
4.580
Amount
91.46K
EV/EBITDA, TTM
0.00

Universe Pharmaceuticals Inc is a holding company primarily engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine drugs (TCMDs) products targeting the elderly. The Company’s products include chronic condition treatments and cold and flu medicines. The chronic condition treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor. The cold and flu medicines primarily include Paracetamol Granule for children, Isatis Root Granule and Qiangli Pipa Syrup. The Company is also engaged in the sales of biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies.

AI analysis of Universe Pharmaceuticals Inc (UPC)

hold

Given the current price of $4.90 and the RSI of 36.176, which indicates that the stock is in the oversold territory, it may not be the best time to buy. However, the recent acquisition of Best Praise International for $10.75 million could provide long-term growth potential. The stock has shown volatility, trading between $2.00 and $11.00 over the past year, and has recently surged over 300% following the acquisition announcement. The main risk is the negative forward P/E of 0, indicating uncertainty in future earnings.

估值指標

The current forward P/E ratio for Universe Pharmaceuticals Inc (UPC) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for UPC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%UPC

$3.96

情境價格

B

Base

Base · 50%UPC

$3.78

情境價格

B

Bear

Bear · 25%UPC

$3.72

情境價格

事件時間軸

2026-06-26 (ET)

16:30:00

Universe Pharmaceuticals Acquires 100% of Best Praise International for $10.751M

2024-12-09 (ET)

06:11:13

Universe Pharmaceuticals to sell 18.75M shares at 80c in direct offering

2024-11-01 (ET)

16:03:26

Universe Pharmaceuticals receives Nasdaq notification over bid price deficiency

資訊

UPC FAQ — answered by Alphio AI

Universe Pharmaceuticals Inc is a holding company primarily engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine drugs (TCMDs) products targeting the elderly. The Company’s products include chronic condition treatments and cold and flu medicines. The chronic condition treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor. The cold and flu medicines primarily include Paracetamol Granule for children, Isatis Root Granule and Qiangli Pipa Syrup. The Company is also engaged in the sales of biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $4.90 and the RSI of 36.176, which indicates that the stock is in the oversold territory, it may not be the best time to buy. However, the recent acquisition of Best Praise International for $10.75 million could provide long-term growth potential. The stock has shown volatility, trading between $2.00 and $11.00 over the past year, and has recently surged over 300% following the acquisition announcement. The main risk is the negative forward P/E of 0, indicating uncertainty in future earnings.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始